Patrick Neven, MD, University Hospitals Leuven, Leuven, Belgium, discusses differences in treating women with breast cancer who are pre-menopausal and post-menopausal. The addition of aromatase inhibitors and ovarian function suppression with existing endocrine therapy benefits pre-menopausal women. Additional caution is needed for people who are peri-menopausal, as ovarian function may still be active. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
